Remdesivir is a less popular drug for antiviral medication, which has become the first medicine approved by the FDA for treating the novel Coronavirus in May 2020. Previously, the drug Remdesivir was regarded as an investigational drug. The drug was never used to treat any disease or any medical condition. Today, the drug is being studied as a probable treatment for several diseases. In the beginning, the drug was created as a potential treatment for hepatitis. The drug was studied as a potential treatment for Ebola virus in 2014. Since then, the effectiveness of the drug has been studied as treatment for any other viruses other than the novel Coronavirus. Also, researchers have found that Remdesivir drug has been proved to be effective against several other (SARS) severe acute respiratory syndrome and also (MERS) Middle East respiratory syndrome, despite the studies were done in the test-tubes and not in animals but on animals.
Major Key Players of the Remdesivir Market are:Gilead Sciences, Inc., BrightGene Bio-Medical Technology Co.,Ltd., Hainan Haiyao Co., Ltd., EVA PHARM, Cipla Inc., Mylan N.V., Hetero, Ferozsons Laboratories, Zydus Cadila, Dr. Reddy's Laboratories Ltd. and Beximco Pharmaceuticals Ltd., among others.
No comments:
Post a Comment